A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.
about
Recombinant bispecific antibodies for cancer therapy.A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.Bi-specific aptamers mediating tumor cell lysis.Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system.A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines.Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.The swinging pendulum of cancer immunotherapy personalization
P2860
Q36013830-8E1E49FA-7F16-40FA-A0CA-2BF5E06E104DQ37593702-7D14EE2F-1503-4485-8738-5D1E11F47A8EQ37717652-1BBFEB8C-1240-4C52-8F40-14992D176973Q38335529-7424F98D-F9CD-427F-B6C7-966F22CF942EQ38698179-AD5F6223-60C4-4608-9190-7DADBA1BEA4EQ39397717-D10DF264-63AF-4D96-A421-82C3C1DA4826Q39445052-430A3C58-41DB-401A-A24B-0DF9916E0A93Q39917871-7E032E81-7B7B-4BA9-8442-EA4E78405413Q40002915-7723D17E-47E5-4C89-A19D-DDFA7C3FCDB9Q40135352-75FE40EC-3494-46CD-9232-4A9E6D84E0E3Q50042227-B608FB3F-80CD-4136-A8B5-31642A24F6A0Q50204340-156C233D-A206-4EC3-A754-81AEEBEF5688Q58924840-37E54303-E9FB-4162-BBBC-E4D654D3EF21
P2860
A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
A recombinant bispecific singl ...... ctive lysis of lymphoma cells.
@ast
A recombinant bispecific singl ...... ctive lysis of lymphoma cells.
@en
type
label
A recombinant bispecific singl ...... ctive lysis of lymphoma cells.
@ast
A recombinant bispecific singl ...... ctive lysis of lymphoma cells.
@en
prefLabel
A recombinant bispecific singl ...... ctive lysis of lymphoma cells.
@ast
A recombinant bispecific singl ...... ctive lysis of lymphoma cells.
@en
P2093
P2860
P1476
A recombinant bispecific singl ...... ctive lysis of lymphoma cells.
@en
P2093
Barbara Fischer
Fritz Titgemeyer
Georg H Fey
Karin Barbin
Katja Schreiter
Kerstin Mahr
Matthias Peipp
Roland Repp
Susan J Zunino
Thomas Valerius
P2860
P304
P356
10.1111/J.1365-2141.2004.04893.X
P407
P577
2004-04-01T00:00:00Z